In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Legend Biotech Corporation (NASDAQ:LEGN), with a market capitalization of $6.74 billion, has emerged as a prominent player in the biotechnology sector, primarily due to the success of its flagship ...

Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...

Janney Montgomery Scott LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 47.0% ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

In recent years, the investment landscape has seen a significant shift towards socially responsible investing strategies.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...